Cosfroviximab

A4DAB073 | Phase-II
Zaire Ebolavirus Glycoprotein
G1 / None
Mapp Biopharmaceutical Public Health Agency of Canada National Institute of Allergy and Infectious Diseases
Phase-II
Whole mAb
c13C6-FR1-N
—
Avg A4D Score
-0.6165
Score Range
-0.64 to -0.59
Structures
10
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB073_5ken_J_I 5ken 100% -0.6311 7.0 4.0 -0.4704 -0.675
A4DAB073_5kel_M_O 5kel 100% -0.6247 7.0 4.0 -0.4936 -0.6607
A4DAB073_5ken_Q_P 5ken 100% -0.5948 7.5 4.0 -0.4814 -0.6258
A4DAB073_5kel_J_N 5kel 100% -0.6204 7.0 4.0 -0.4937 -0.6551
A4DAB073_5kel_C_D 5kel 100% -0.6204 7.0 4.0 -0.4941 -0.655
A4DAB073_5kem_I_J 5kem 100% -0.6037 7.5 4.0 -0.496 -0.6332
A4DAB073_5ken_N_O 5ken 48% -0.6094 6.5 9.0 0.002 -0.7665
A4DAB073_5ken_G_H 5ken 48% -0.6166 6.5 9.0 -0.0065 -0.7734
A4DAB073_5kem_D_E 5kem 100% -0.6022 7.5 4.0 -0.4934 -0.632
A4DAB073_5ken_C_D 5ken 48% -0.6422 6.5 9.0 -0.0335 -0.7987